The inaugural issue of the Asian Journal of Advances in Orphan Pharmacotherapy features pioneering research and reviews highlighting the emerging advancements in the diagnosis, treatment, and regulatory policies for rare and orphan diseases.
Featured Articles in the Latest Issue
- Volume 2 (Issue 1) JANUARY- JUNE 2026
Research Articles
Precision RNA Therapeutics for Rare Mitochondrial Disorders: A First-in Human Evaluation
Vol.2(1); Pages:1-9. Published on April-2026
Abstract
Mitochondrial disorders represent a diverse group of rare genetic conditions with limited therapeutic options. This Phase I clinical trial investigates the safety, tolerability, and preliminary efficacy of a novel RNA-based therapeutic designed to modulate mitochondrial gene expression in patients with a rare mitochondrial encephalomyopathy. Twelve adult participants received escalating doses of the investigational agent over a 12 week period. Primary outcomes focused on safety assessments, including adverse event monitoring and laboratory parameters, while secondary outcomes evaluated mitochondrial function through biochemical assays and imaging techniques. The therapy demonstrated a favorable safety profile with no dose-limiting toxicities observed. Preliminary efficacy signals included improved mitochondrial respiration and reduced lactate accumulation. These findings suggest that RNA-targeted approaches may offer a viable therapeutic strategy for mitochondrial disorders, warranting further investigation in larger controlled studies to establish long-term clinical benefits.
View Full PDF
Please LOGIN to View Full PDF or Read more.
CRISPR-Based Therapeutics in Rare Hematological Disorders: A Translational Study
Vol.2(1); Pages:10-18. Published on May-2026
Abstract
Recent advances in CRISPR-Cas9 gene editing technologies have opened new avenues for treating rare hematological disorders characterized by monogenic mutations. This translational study investigates the feasibility of ex vivo CRISPR-mediated correction of a pathogenic mutation in hematopoietic stem cells derived from patients with a rare congenital anemia. Edited cells were assessed for genomic integrity, off-target effects, and functional restoration through in vitro differentiation assays. Following successful editing, corrected cells were transplanted into immunodeficient murine models to evaluate engraftment and hematopoietic reconstitution. Results indicate high editing efficiency with minimal off-target activity, as confirmed by whole genome sequencing. Functional assays demonstrated restored erythropoiesis and normalized hemoglobin production. In vivo studies further validated sustained engraftment and multilineage differentiation. These findings support the translational potential of CRISPR-based interventions in orphan hematological conditions and highlight the need for carefully designed clinical trials to address long-term safety and ethical considerations.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Nanocarrier-Mediated Drug Delivery for Rare Pediatric Neurodegenerative Disorders
Vol.2(1); Pages:19-28. Published on May-2026
Abstract
Delivering therapeutics across the blood-brain barrier remains a significant obstacle in treating rare pediatric neurodegenerative disorders. This preclinical study explores the use of lipid-based nanocarriers engineered for targeted delivery of neuroprotective agents in a murine model of a rare inherited neurodegenerative disease. Nanocarriers were functionalized with ligands to enhance receptor-mediated transcytosis and evaluated for drug encapsulation efficiency, stability, and release kinetics. In vivo administration demonstrated successful penetration of the blood-brain barrier and selective accumulation in affected neural tissues. Behavioral and histopathological assessments revealed significant neuroprotection, reduced neuronal loss, and improved cognitive function compared to control groups. Toxicological analysis confirmed biocompatibility and absence of systemic toxicity. These findings underscore the potential of nanocarrier systems in overcoming pharmacological barriers in orphan neurological diseases and provide a foundation for future clinical translation in pediatric populations.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Pharmacovigilance Patterns in Orphan Drug Use: A Multi-NationalRetrospective Analysis
Vol.2(1); Pages:29-38. Published on June-2026
Abstract
Orphan drugs often enter the market with limited clinical data, necessitating robust pharmacovigilance to monitor long-term safety. This retrospective cohort study analyzes adverse drug reaction (ADR) patterns associated with orphan drug use across five countries over a ten-year period. Data were extracted from national pharmacovigilance databases and categorized based on drug class, patient demographics, and severity of reported events. Statistical analysis identified trends in ADR frequency and correlations with specific therapeutic categories. Findings revealed a higher incidence of moderate to severe ADRs in biologic orphan drugs compared to small-molecule therapies. Notably, pediatric populations exhibited distinct safety profiles, emphasizing the need for age-specific monitoring frameworks. The study also highlighted inconsistencies in reporting standards across regions, suggesting a need for harmonized global pharmacovigilance protocols. These insights contribute to improving post-marketing surveillance and optimizing risk management strategies in orphan pharmacotherapy.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Economic Evaluation of Ultra-Orphan Drugs: Cost-Effectiveness in Limited Populations
Vol.2(1); Pages:39-48. Published on June-2026
Abstract
The high cost of ultra-orphan drugs presents significant challenges for healthcare systems, particularly when evaluating their cost-effectiveness in extremely small patient populations. This study conducts a comprehensive economic evaluation of three recently approved ultra-orphan therapies using a Markov model framework. Data inputs included clinical efficacy, quality-adjusted life years (QALYs), and direct healthcare costs derived from published trials and national health databases. Incremental cost-effectiveness ratios (ICERs) were calculated and compared against established willingness-to-pay thresholds in different healthcare settings. Results indicate that while ultra-orphan drugs often exceed conventional ICER thresholds, they provide substantial gains in patient survival and quality of life. Sensitivity analyses demonstrated that pricing adjustments and alternative reimbursement models, such as outcome-based agreements, could improve economic viability. The study underscores the importance of flexible evaluation frameworks tailored to rare diseases and supports policy innovations to ensure equitable access to life.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Accessing the Articles
You can access the full text of these articles by clicking on the titles or visiting our journal’s online archives.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
